Impaired left ventricular systolic function early after heart transplantation is associated with cardiac allograft

I A Bolad1, D R Robinson, C Webb

  • 1Transplant Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Hill End Road, Harefield, Middlesex UB9 6JH, UK.

Insights

Early left ventricular systolic dysfunction after heart transplantation predicts cardiac allograft vasculopathy (CAV). Lower initial fractional shortening (FS) is linked to greater mean lumen diameter loss (MLDL), a key indicator of CAV development.

Area of Science:

  • Cardiology
  • Transplantation Immunology

Background:

  • Cardiac allograft vasculopathy (CAV) is a leading cause of late mortality post-heart transplantation.
  • Identifying predictive factors for CAV is crucial for improving long-term patient survival.

Purpose of the Study:

  • To investigate the role of etiological factors in the development of CAV.
  • To assess the predictive value of various factors on CAV progression using quantitative coronary angiography (QCA).

Main Methods:

  • 121 heart transplant recipients underwent baseline QCA; 117 had a 1-year follow-up QCA.
  • Mean lumen diameter loss (MLDL) was measured in main coronary arteries.
  • Association of MLDL with immunological and non-immunological factors was analyzed via univariate and multivariate models.

Main Results:

  • Univariate analysis revealed MLDL inversely correlated with early echocardiographic fractional shortening (FS) and donor intracranial hemorrhage, and directly with male donors, domino transplants, and donor cytomegalovirus (CMV) negativity.
  • Multivariate analysis identified initial FS and donor intracranial hemorrhage as inversely related to MLDL.
  • Donor male sex and continuous prednisolone treatment were directly related to MLDL.

Conclusions:

  • Early left ventricular systolic dysfunction, indicated by reduced initial FS, is associated with subsequent CAV development.
  • Donor characteristics and immunosuppressive therapy (prednisolone) also play a role in CAV pathogenesis.